文献速递临床试验与 GCP

帕金森病运动研究3期(SPARX3):一项随机对照试验的研究方案

Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2022-10-06

SPARX3是一项多中心、随机、评估者盲法的3期临床试验,计划随机370例确诊3年内且未接受症状治疗的帕金森病患者,比较跑步机中等强度与高强度耐力运动18个月对MDS-UPDRS运动评分(Part III)12个月变化的影响。

要点

  • 比较跑步机中等强度(60-65%最大心率)与高强度(80-85%最大心率)耐力运动对帕金森病进展的影响。
  • 主要结局为12个月内MDS-UPDRS运动评分(Part III)变化,或至开始症状治疗。
  • 计划随机370例,干预18个月,随访24个月。

核心结论

  • SPARX3旨在确定高强度跑步机耐力运动能否延缓帕金森病进展(以MDS-UPDRS运动评分衡量)。

研究设计与样本

  • 多中心、随机、评估者盲法的耐力运动训练研究。
  • 计划随机370例确诊3年内且基线未接受症状治疗的帕金森病患者。
  • 跑步机运动干预18个月:中等强度(4天/周,每次30分钟,60-65%最大心率)与高强度(4天/周,每次30分钟,80-85%最大心率)。
  • 随访24个月,多个时间点评估。

主要发现

  • 主要分析评估12个月内MDS-UPDRS运动评分(Part III)变化,或至开始症状性抗帕金森病治疗(若在12个月之前)。
  • 次要结局包括纹状体多巴胺转运体结合、6分钟步行距离、每日步数、认知功能、体能、生活质量、开始多巴胺能药物治疗时间、循环C反应蛋白(CRP)和脑源性神经营养因子(BDNF)水平。
  • 三级结局包括步行步长和转身速度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To date, no medication has slowed the progression of Parkinson's disease (PD). Preclinical, epidemiological, and experimental data on humans all support many benefits of endurance exercise among persons with PD. The key question is whether there is a definitive additional benefit of exercising at high intensity, in terms of slowing disease progression, beyond the well-documented benefit of endurance training on a treadmill for fitness, gait, and functional mobility. This study will determine the efficacy of high-intensity endurance exercise as first-line therapy for persons diagnosed with PD within 3 years, and untreated with symptomatic therapy at baseline. METHODS: This is a multicenter, randomized, evaluator-blinded study of endurance exercise training. The exercise intervention will be delivered by treadmill at 2 doses over 18 months: moderate intensity (4 days/week for 30 min per session at 60-65% maximum heart rate) and high intensity (4 days/week for 30 min per session at 80-85% maximum heart rate). We will randomize 370 participants and follow them at multiple time points for 24 months. The primary outcome is the Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor score (Part III) with the primary analysis assessing the change in MDS-UPDRS motor score (Part III) over 12 months, or until initiation of symptomatic antiparkinsonian treatment if before 12 months. Secondary outcomes are striatal dopamine transporter binding, 6-min walk distance, number of daily steps, cognitive function, physical fitness, quality of life, time to initiate dopaminergic medication, circulating levels of C-reactive protein (CRP), and brain-derived neurotrophic factor (BDNF). Tertiary outcomes are walking stride length and turning velocity. DISCUSSION: SPARX3 is a Phase 3 clinical trial designed to determine the efficacy of high-intensity, endurance treadmill exercise to slow the progression of PD as measured by the MDS-UPDRS motor score. Establishing whether high-intensity endurance treadmill exercise can slow the progression of PD would mark a significant breakthrough in treating PD. It would have a meaningful impact on the quality of life of people with PD, their caregivers and public health. TRIAL REGISTRATION: ClinicalTrials.gov NCT04284436 . Registered on February 25, 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Patterson CG, Joslin E, Gil AB, et al. Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial. Trials. 2022. PMID: 36203214. doi:10.1186/s13063-022-06703-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。